This topic contains 1 reply, has 2 voices, and was last updated by Krista Rubin February 1, 2018 at 3:46 am.

Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • #4644

    Hello,

    What can you tell us about the use of Shingrix in patients receiving immunotherapy? I know it probably hasn’t been studied yet in this setting, but do you suspect that it would be safer than Zostavax in this setting (theoretically)?

    #4645
    Expert Nurse
    Krista Rubin
    Krista Rubin

    HI Lisa- you ask an excellent question.

    – Shingrix is non-live, recombinant vaccine just recently approved for prevention of zoster.
    – Zostavax is a live, attenuated vaccine approved for prevention of zoster.

    Given the recommendation to avoid live vaccines while on immunotherapy, Shingrix would be the better of the two choices. Agreed- we do not have data regarding safety of use in the setting of immune therapy, specifically immune checkpoint inhibitors, but theoretically…..

    This may be an ideal option for patients at risk; and importantly, prevention of zoster prevents associated post-herpetic neuralgia—this is debilitating for some individuals.

    Thanks for posing this question Lisa.

Viewing 2 posts - 1 through 2 (of 2 total)

You must be logged in to reply to this topic.